Skip to main content

Advertisement

Log in

Barrett esophagus

Treatment without histology—a dangerous affair

  • News & Views
  • Published:

From Nature Reviews Gastroenterology & Hepatology

View current issue Sign up to alerts

A recent position paper by the American Gastroenterological Association has made a range of excellent recommendations for the management of patients with Barrett esophagus. However, the guidelines have several important limitations, including the omission of endoscopic therapy for patients who have T1 Barrett adenocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Spechler, S. J. et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 140, 1084–1091 (2011).

    Article  PubMed  Google Scholar 

  2. Ell, C. et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 118, 670–677 (2000).

    Article  CAS  PubMed  Google Scholar 

  3. Pech, O. et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 57, 1200–1206 (2008).

    Article  CAS  PubMed  Google Scholar 

  4. Pouw, R. E. et al. Properties of the neosquamous epithelium after radiofrequency ablation of Barrett's esophagus containing neoplasia. Am. J. Gastroenterol. 104, 1366–1373 (2009).

    Article  PubMed  Google Scholar 

  5. Stefanidis, D. et al. Guidelines for surgical treatment of gastroesophageal reflux disease. Surg. Endosc. 24, 2647–2669 (2010).

    Article  PubMed  Google Scholar 

  6. Moss, A. et al. Endoscopic resection for Barrett's high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefit. Am. J. Gastroenterol. 105, 1276–1283 (2010).

    Article  PubMed  Google Scholar 

  7. Konda, V. J. et al. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? Clin. Gastroenterol. Hepatol. 6, 159–164 (2008.

    Article  PubMed  Google Scholar 

  8. Oh, D. S. et al. Clinical biology and surgical therapy of intramucosal adenocarcinoma of the esophagus. J. Am. Coll. Surg. 203, 152–161 (2006.

    Article  PubMed  Google Scholar 

  9. Stein, H. J. et al. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann. Surg. 242, 566–573 (2005).

    PubMed  PubMed Central  Google Scholar 

  10. Pech, O. et al. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Ann. Surg. doi:10.1097/SLA.0b013e31821d4bf6.

    Article  PubMed  Google Scholar 

  11. Manner H. et al. Final results of a prospective randomized trial on thermal ablation of Barrett's mucosa with concomitant esomeprazole treatment versus surveillance plus PPI in patients cured from early Barrett's cancer by endoscopic resection (APE Study) [abstract]. Gastrointest. Endosc. 78 (Suppl. 1), AB197 (2011).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Oliver Pech.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Behrens, A., Pech, O. Treatment without histology—a dangerous affair. Nat Rev Gastroenterol Hepatol 8, 364–366 (2011). https://doi.org/10.1038/nrgastro.2011.98

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2011.98

  • Springer Nature Limited

Navigation